Initiated with a Buy: Arcellx, Pliant Therapeutics, Tarsus Pharmaceuticals, Varonis Systems
- May 18th, 2023
- 296 views
Several companies have recently received initiations with Buy ratings from prominent financial institutions, indicating positive outlooks for their future performance.
Arcellx, Inc. (Nasdaq: ACLX) has been initiated with a Buy rating and a price target of $60 by Truist. In pre-market trading, $ACLX is currently trading at $41.34, with a slight increase of $0.10 (+0.24%).
Pliant Therapeutics, Inc. (Nasdaq: PLRX) has received a Buy rating from Canaccord Genuity, along with a price target of $48. $PLRX is trading at $21.75 in pre-market, showing a gain of $0.22 (+1.02%).
Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) has been initiated with a Buy rating by Guggenheim. In pre-market trading, $TARS is trading at $16.41, experiencing a significant increase of $0.48 (+3.01%).
Varonis Systems, Inc. (Nasdaq: VRNS) has received a Buy rating and a price target of $30 from DA Davidson. However, in pre-market trading, $VRNS is currently trading at $22.81, facing a decrease of $1.20 (-5.00%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Earnings Due: Wall Street Eyes Goldman Sachs, Fastenal, FB Financial
April 12th, 2026Treasury Launches Cybersecurity Information Sharing Initiative for the Digital Asset Industry
April 09th, 2026How Eligibility Protection Is Creating New Opportunities for Football Athletes After High School
April 08th, 2026Cryptocurrency and AI Scams Bilk Americans of Billions
April 06th, 2026
Member Login